Study event | Female | P trend | Male | P trend | ||||||
n=181 | n=174 | n= 148 | n= 73 | n= 247 | n= 671 | n= 218 | n= 154 | |||
IMACE risk category | IMACE risk category | |||||||||
Low | Mild | Mod | High | Low | Mild | Mod | High | |||
≤2 (%) | 3–4 (%) | 5–6 (%) | ≥7 (%) | ≤2 (%) | 3–5 (%) | 6–7 (%) | ≥8 (%) | |||
Primary outcome: MACE (composite of CV death, MI and stroke) | ||||||||||
Composite endpoint | 5.0 | 4.0 | 17.6 | 32.9 | <0.001 | 4.5 | 4.8 | 12.4 | 19.5 | <0.001 |
Secondary outcomes | ||||||||||
MI | 1.7 | 1.1 | 4.1 | 9.6 | <0.001 | 2.8 | 2.5 | 6.0 | 5.8 | 0.012 |
Stroke | 0.6 | 0.0 | 2.7 | 4.1 | 0.005 | 0.0 | 0.3 | 2.8 | 0.6 | 0.016 |
CV mortality | 2.8 | 3.4 | 12.2 | 21.9 | <0.001 | 1.6 | 2.4 | 6.0 | 14.3 | <0.001 |
All-cause mortality | 3.9 | 4.6 | 16.9 | 30.1 | <0.001 | 2.8 | 3.3 | 8.3 | 17.5 | <0.001 |
Sex-specific IMACE results are categorised as low, mild, moderate (mod) and high risk.
CV, cardiovascular; IMACE, Intermountain Major Adverse Cardiovascular Events; MACE, major adverse cardiovascular events; MI, myocardial infarction.